Table 3.

Frailty analysis in MAIA, ALCYONE, and HOVON143 study results

	MAIA48		ALCYONE70		HOVON14367
Follow-up (median), mo	36.4∗		40.1∗		22.9
Frail patients, %	46.7		44.6		100

	DRd	Rd	D-VMP	VMP	IDd
PFS in frail patients, (median), mo	NR	30.4	32.9	19.5	13.8
ORR, %	87.2	78.1	88.3	72.4	78
Death within 60 d, %	6	3.6	4.4†	5.3†	8
Grade ≥3 treatment-emergent adverse events, %	94.6	89.2	79.4	81.5	30 (hematologic) 74 (nonhematologic)
Grade ≥3 pneumonia, %	19.6	10.2	14.4	5.3	NR

^∗OS results not presented (not mature).

^†Unpublished, from clinical study report.